Which of the following drugs is not used in the treatment of akathisia?
What is the primary mechanism of action of zonisamide?
All are symptoms of morphine withdrawal except?
Botulinum toxin acts on
Botulinum toxin type B is used in which disease?
Which of the following is a benzylisoquinoline muscle relaxant?
Which is a GABA transaminase inhibitor?
Which anxiolytic acts through 5-HT1A receptor partial agonism without exhibiting significant anticonvulsant or muscle relaxant properties?
Which of the following drugs is used for Smoking Cessation?
Which dopamine receptor is known for its inhibitory action in the central nervous system?
Explanation: ***Haloperidol*** - **Haloperidol** is a typical antipsychotic drug known to **cause** or worsen **akathisia**, rather than treat it. - Akathisia is an extrapyramidal symptom, and **first-generation antipsychotics** like haloperidol are frequent culprits due to their strong **D2 receptor blockade**. *Benzodiazepine* - **Benzodiazepines** like lorazepam or clonazepam are often used to treat akathisia due to their **sedative** and **anxiolytic** properties. - They act by enhancing **GABAergic transmission**, which can help calm the motor restlessness associated with akathisia. *Propranolol* - **Propranolol**, a **beta-blocker**, is a first-line treatment for akathisia, particularly effective for its objective motor symptoms. - It works by reducing **adrenergic activity**, which is thought to contribute to the motor restlessness. *Trihexyphenidyl* - **Trihexyphenidyl** is an **anticholinergic** agent primarily used to treat **parkinsonian-like extrapyramidal symptoms** (e.g., dystonia, pseudoparkinsonism). - While sometimes used for generalized EPS, it is **less effective** for the specific motor restlessness of akathisia compared to beta-blockers or benzodiazepines.
Explanation: ***Sodium channels (Correct Answer)*** - Zonisamide's primary mechanism involves **blocking voltage-sensitive sodium channels**, which stabilizes neuronal membranes and inhibits repetitive neuronal firing. - This action helps to prevent the propagation of **seizure activity** in the brain. *GABA receptors* - While zonisamide has some weak effects on GABA, it is not its **primary mechanism of action** for antiepileptic efficacy. - Drugs like **benzodiazepines** and **barbiturates** primarily act by enhancing GABAergic transmission. *T-type calcium channels* - Zonisamide also blocks T-type calcium channels, contributing to its broad-spectrum antiepileptic activity, but this is a **secondary mechanism** compared to its sodium channel blockade. - **Ethosuximide** is a classic example of a drug primarily acting on T-type calcium channels, especially for absence seizures. *Cl- channels* - Zonisamide does not primarily act on **chloride channels**; these are often modulated by GABA receptors. - Drugs that act directly on chloride channels are not typically used as **antiepileptics** in the same way.
Explanation: ***Fall in BP*** - **Hypotension (fall in BP)** is **not** typically a symptom of opioid withdrawal; rather, **hypertension** can occur due to sympathetic overdrive. - Opioid withdrawal symptoms are primarily characterized by **hyperactivity** and increased sympathetic nervous system activity. *Mydriasis* - **Mydriasis (dilated pupils)** is a classic symptom of opioid withdrawal, resulting from reduced parasympathetic tone and increased sympathetic activity. - In contrast, opioid intoxication causes **miosis (pinpoint pupils)**. *Yawning* - **Yawning** is a very common and early symptom of opioid withdrawal, often accompanied by feelings of fatigue and restlessness. - It reflects generalized **autonomic dysregulation** during withdrawal. *Lacrimation* - **Lacrimation (tearing)** is another prominent autonomic symptom of opioid withdrawal. - This, along with rhinorrhea, contributes to the **"flu-like" symptoms** experienced during withdrawal.
Explanation: ***Synapse*** - **Botulinum toxin** acts by inhibiting the release of **acetylcholine** at the **neuromuscular junction**, which is a type of synapse. - This blockade of neurotransmitter release at the **presynaptic terminal** prevents muscle contraction, leading to paralysis. *Smooth muscle of intestine* - While botulinum toxin can affect smooth muscle indirectly by paralyzing the motor nerves innervating them, its primary site of action is the **synapse** itself, not directly on the muscle fibers. - The toxin primarily targets the nerve endings, rather than the mechanical contractility of the muscle cell. *Central nervous system* - **Botulinum toxin** does not readily cross the **blood-brain barrier**, meaning its primary effects are peripheral. - Its therapeutic and toxic effects are localized to the **peripheral nervous system** and neuromuscular junctions. *Sensory nerves* - **Botulinum toxin** specifically targets **motor nerve endings** to inhibit acetylcholine release, leading to muscle paralysis. - It does not directly affect the function of **sensory nerve transmission** or pain perception in the same way.
Explanation: ***Cervical dystonia*** * **Botulinum toxin type B (Myobloc/NeuroBloc)** is specifically approved for the treatment of **cervical dystonia**, which involves involuntary contractions of neck muscles. * It works by blocking the release of **acetylcholine** at the neuromuscular junction, leading to muscle relaxation. *Strabismus* * **Botulinum toxin type A (Botox, Dysport, Xeomin)** is the preferred and most commonly used form for treating **strabismus** by temporarily weakening specific extraocular muscles. * Type B is generally not indicated for strabismus due to differences in potency and duration of action. *Blepharospasm* * **Botulinum toxin type A** (e.g., Botox) is the primary treatment for **blepharospasm**, an involuntary forceful closure of the eyelids. * While both types inhibit acetylcholine release, type A has a more established and concentrated use in treating localized muscle spasms like blepharospasm. *Glabellar lines* * **Botulinum toxin type A** is widely used for cosmetic applications such as reducing **glabellar lines** (frown lines between the eyebrows). * Its efficacy and safety for cosmetic indications are well-established, making type A the standard choice over type B.
Explanation: ***Doxacurium*** - **Doxacurium** is a long-acting, non-depolarizing neuromuscular blocker classified as a **benzylisoquinoline** compound [1]. - These agents are known for their minimal cardiovascular effects and lack of histamine release in therapeutic doses [1]. *Vecuronium* - **Vecuronium** is an **aminosteroid** non-depolarizing neuromuscular blocker [2]. - It is known for its intermediate duration of action and minimal cardiovascular effects [1]. *Rocuronium* - **Rocuronium** is also an **aminosteroid** non-depolarizing neuromuscular blocker [2]. - It has a rapid onset of action, making it suitable for rapid sequence intubation, and can be reversed by **sugammadex**. *Pancuronium* - **Pancuronium** is an **aminosteroid** non-depolarizing neuromuscular blocker with a long duration of action [1]. - It is associated with a vagolytic effect that can cause an increase in **heart rate** and **blood pressure** [1].
Explanation: ***Valproate*** - Valproate is known to inhibit **GABA transaminase**, an enzyme responsible for the breakdown of **gamma-aminobutyric acid (GABA)**. - By inhibiting this enzyme, valproate increases the concentration of **GABA** in the brain, enhancing its inhibitory effects and contributing to its anticonvulsant properties. *TCA* - **Tricyclic antidepressants (TCAs)** primarily work by inhibiting the reuptake of **norepinephrine** and **serotonin** in the brain. - They do not directly inhibit GABA transaminase but rather modulate monoamine neurotransmission. *Sertraline* - **Sertraline** is a **selective serotonin reuptake inhibitor (SSRI)** that works by blocking the reabsorption of **serotonin** into presynaptic neurons. - Its primary mechanism of action is focused on serotonin pathways, not on GABA metabolism. *Gabapentin* - **Gabapentin** is an anticonvulsant that is thought to exert its effects by modulating **calcium channels** and increasing **GABA synthesis**, but it is not a direct inhibitor of GABA transaminase. - Its mechanism of action is distinct from directly preventing GABA breakdown.
Explanation: ***Buspirone*** - **Buspirone** is a unique anxiolytic that primarily acts as a **partial agonist at 5-HT1A receptors**. - Unlike benzodiazepines, it lacks significant **anticonvulsant**, **muscle relaxant**, or **sedative-hypnotic properties** and does not lead to physical dependence or withdrawal. *Diazepam* - **Diazepam** is a **benzodiazepine** that acts by enhancing the effect of **GABA** at GABA-A receptors, leading to significant anxiolytic, sedative, muscle relaxant, and anticonvulsant effects. - It does not primarily act via **5-HT1A receptor partial agonism**. *Zolpidem* - **Zolpidem** is a **non-benzodiazepine hypnotic** that selectively binds to the **GABA-A receptor** subunit, primarily mediating sedative effects. - While it's used for insomnia, it doesn't primarily act as a **5-HT1A partial agonist** and is not typically used for its anxiolytic properties in the same way as buspirone. *Phenobarbitone* - **Phenobarbitone** is a **barbiturate** that acts by prolonging the opening of **chloride channels** associated with GABA-A receptors, leading to strong sedative, hypnotic, and anticonvulsant effects. - Its mechanism of action is distinct from **5-HT1A receptor partial agonism**, and it carries a high risk of dependence and overdose.
Explanation: ***Bupropion*** - **Bupropion** is an antidepressant that is also approved as a smoking cessation aid. It works by inhibiting the reuptake of **dopamine** and **norepinephrine**, which can help reduce nicotine cravings and withdrawal symptoms. - It is often prescribed as a first-line pharmacotherapy for smoking cessation, with a typical treatment duration of 7-12 weeks. *Buprenorphine* - **Buprenorphine** is a partial opioid agonist primarily used to treat opioid addiction. It is not indicated for smoking cessation. - While it can help manage withdrawal symptoms from opioids, it has no direct mechanism of action that would reduce nicotine dependence or cravings. *Methadone* - **Methadone** is a full opioid agonist primarily used for the treatment of opioid use disorder (OUD) and chronic pain management. It is not used for smoking cessation. - Its mechanism involves binding to opioid receptors to prevent withdrawal symptoms and reduce cravings for other opioids. *Naltrexone* - **Naltrexone** is an opioid antagonist used primarily for the treatment of alcohol dependence and opioid use disorder. It is not indicated for smoking cessation. - It blocks the effects of opioids and reduces alcohol cravings, but does not affect nicotine pathways or dependence.
Explanation: ***Dopamine Receptor D2*** - The **D2 receptor** is a member of the D2-like family (D2, D3, D4), which are **G-protein coupled receptors** that inhibit adenylyl cyclase activity. - Its activation typically leads to a **decrease in neuronal excitability** and neurotransmitter release, providing an inhibitory effect in the CNS. *Dopamine Receptor D5* - The **D5 receptor** belongs to the D1-like family (D1, D5), which are **G-protein coupled receptors** that stimulate adenylyl cyclase activity. - Activation of D5 receptors typically leads to **excitatory effects** rather than inhibitory ones in the CNS. *No inhibitory dopamine receptor present* - This statement is incorrect as specific dopamine receptor subtypes, particularly the **D2-like family**, are well-established to exert inhibitory actions in the CNS. - These inhibitory effects are crucial for various physiological processes, including motor control and reward pathways. *Dopamine Receptor D1* - The **D1 receptor** is part of the D1-like family (D1, D5) and is known for its **excitatory effects** in the CNS. - Activation of D1 receptors leads to an **increase in intracellular cAMP** and generally enhances neuronal activity.
General Anesthetics
Practice Questions
Local Anesthetics
Practice Questions
Sedative-Hypnotics
Practice Questions
Antiepileptic Drugs
Practice Questions
Antiparkinsonian Drugs
Practice Questions
Opioid Analgesics
Practice Questions
Drugs of Abuse and Addiction
Practice Questions
Psychostimulants
Practice Questions
Hallucinogens
Practice Questions
CNS Stimulants and Cognitive Enhancers
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free